MedTrace Logo

Staccato Alprazolam and Photoparoxysmal Response

NCT02351115 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-04-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether people who usually have photosensitive epilepsy will show a reduction in epileptic activity when they take a single dose of Staccato Alprazolam as compared to placebo.

Conditions

Interventions

DRUG

A=Placebo

DRUG

B=Inhaled Alprazolam 0.5 mg

DRUG

C=Inhaled Alprazolam 1 m

DRUG

D= Inhaled Alprazolam 2 mg

DRUG

E=Placebo

Sponsors & Collaborators

  • The Epilepsy Study Consortium

    collaborator OTHER

  • Nova Pneuma Inc.

    lead INDUSTRY

Principal Investigators

  • J Isojarvi, MD · Engage Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-07-31
Completion
2016-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02351115 on ClinicalTrials.gov